Jiayan Wei
Overview
Explore the profile of Jiayan Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Feng J, Chen X, Weng Y, Wang T, Wei J, et al.
Aging (Albany NY)
. 2024 Apr;
16(8):7331-7356.
PMID: 38656888
Background: Patients with gastric cancer respond poorly to immunotherapy. There are still unknowns about the biomarkers associated with immunotherapy sensitivity and their underlying molecular mechanisms. Methods: Gene expression data for...
2.
Wei J, Wang J, Chen X, Zhang L, Peng M
PeerJ
. 2024 Feb;
12:e16819.
PMID: 38317842
Hepatocellular carcinoma (HCC) stands as the prevailing manifestation of primary liver cancer and continues to pose a formidable challenge to human well-being and longevity, owing to its elevated incidence and...
3.
Feng J, Chen X, Wei J, Weng Y, Wang J, Wang T, et al.
Sci Rep
. 2024 Jan;
14(1):2315.
PMID: 38281979
We conducted a retrospective study to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in patients with advanced non-small cell lung cancer (NSCLC). The study included 111 patients who...
4.
Wang Y, Zhang H, Liu L, Li Z, Zhou Y, Wei J, et al.
Front Aging Neurosci
. 2023 Aug;
15:1229559.
PMID: 37600511
Introduction: Cognitive decline in the elderly population is a growing concern, and vascular factors, such as hypertension, diabetes, cerebrovascular disease, and coronary heart disease, have been associated with cognitive impairments....
5.
Wang J, Cui X, Weng Y, Wei J, Chen X, Wang P, et al.
Front Genet
. 2023 Feb;
14:1092968.
PMID: 36816016
Lung adenocarcinoma (LUAD) is an essential pathological subtype of non-small cell lung cancer and offers a severe problem for worldwide public health. There is mounting proof that angiogenesis is a...
6.
Jin Y, Wei J, Weng Y, Feng J, Xu Z, Wang P, et al.
Front Oncol
. 2022 Mar;
12:732814.
PMID: 35280727
Background: Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment of patients with advanced tumors. However, little is known about their efficacy and safety in adjuvant settings...
7.
Wei J, Feng J, Weng Y, Xu Z, Jin Y, Wang P, et al.
Front Oncol
. 2021 Oct;
11:706910.
PMID: 34660274
Background: Circulating tumor DNA (ctDNA) levels and blood tumor mutation burden (bTMB) have a significant impact on the prognosis of tumor patients. However, their prognostic role in immune checkpoint inhibitors...